745.77
price down icon0.11%   -0.84
after-market Dopo l'orario di chiusura: 734.12 -11.65 -1.56%
loading
Precedente Chiudi:
$746.61
Aprire:
$754.55
Volume 24 ore:
438.13K
Relative Volume:
0.55
Capitalizzazione di mercato:
$78.84B
Reddito:
$14.34B
Utile/perdita netta:
$4.50B
Rapporto P/E:
17.94
EPS:
41.5626
Flusso di cassa netto:
$3.77B
1 W Prestazione:
-1.85%
1M Prestazione:
-7.15%
6M Prestazione:
+33.17%
1 anno Prestazione:
+9.57%
Intervallo 1D:
Value
$741.89
$758.98
Intervallo di 1 settimana:
Value
$741.89
$788.69
Portata 52W:
Value
$476.49
$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,410
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2026-01-30
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
745.77 78.84B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.34 119.23B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
ARGX
Argen X Se Adr
700.45 43.35B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.41 41.57B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
284.05 31.51B 5.36B 287.73M 924.18M 2.5229

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-06 Iniziato Barclays Overweight
2026-01-07 Aggiornamento BofA Securities Underperform → Buy
2025-12-03 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-11-24 Iniziato HSBC Securities Buy
2025-11-24 Ripresa Truist Buy
2025-11-13 Iniziato Scotiabank Sector Perform
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
Mar 14, 2026

Regeneron Pharmaceuticals (REGN) Valuation Check After Recent Share Price Cooling - simplywall.st

Mar 14, 2026
pulisher
Mar 14, 2026

Suvretta Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dodge & Cox - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Game Creek Capital LP Has $2.77 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 14, 2026
pulisher
Mar 13, 2026

Is Eli Lilly's Weight Loss Empire in Trouble? - The Motley Fool

Mar 13, 2026
pulisher
Mar 13, 2026

Tocqueville Asset Management L.P. Sells 6,884 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 13, 2026
pulisher
Mar 13, 2026

Regeneron Pharmaceuticals Hits Day Low of $744 Amid Price Pressure - Markets Mojo

Mar 13, 2026
pulisher
Mar 13, 2026

Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Sq - AD HOC NEWS

Mar 13, 2026
pulisher
Mar 13, 2026

Quadrature Capital Ltd Has $34.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 13, 2026
pulisher
Mar 12, 2026

Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - AOL.com

Mar 12, 2026
pulisher
Mar 12, 2026

The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD for the treatment of a rare pediatric disease. - Bitget

Mar 12, 2026
pulisher
Mar 12, 2026

Mackenzie Financial Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Capital Research Global Investors Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com

Mar 12, 2026
pulisher
Mar 12, 2026

2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - AOL.com

Mar 12, 2026
pulisher
Mar 12, 2026

A Look At Regeneron Pharmaceuticals (REGN) Valuation After Positive Obesity Phase 3 Trial Results - Yahoo Finance

Mar 12, 2026
pulisher
Mar 11, 2026

Regeneron Science Talent Search: Jericho High senior Ashka Shah recounts experience at finals in D.C. - Newsday

Mar 11, 2026
pulisher
Mar 11, 2026

Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN) - Seeking Alpha

Mar 11, 2026
pulisher
Mar 11, 2026

WINTON GROUP Ltd Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Franklin Resources Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Richard Bernstein Advisors LLC Sells 2,449 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Legal & General Group Plc Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Capital World Investors Acquires 32,348 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lowered by Capital International Inc. CA - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Capital International Investors Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Capital Group Private Client Services Inc. - MarketBeat

Mar 11, 2026
pulisher
Mar 10, 2026

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - The Manila Times

Mar 10, 2026
pulisher
Mar 10, 2026

Regeneron Science Talent Search 2026 Recognizes America’s - GlobeNewswire

Mar 10, 2026
pulisher
Mar 10, 2026

Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative? - simplywall.st

Mar 10, 2026
pulisher
Mar 10, 2026

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More ... - Caledonian Record

Mar 10, 2026
pulisher
Mar 10, 2026

Jefferies raises Regeneron stock price target on obesity drug data By Investing.com - Investing.com South Africa

Mar 10, 2026
pulisher
Mar 10, 2026

Jefferies raises Regeneron stock price target on obesity drug data - Investing.com

Mar 10, 2026
pulisher
Mar 10, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 10, 2026
pulisher
Mar 10, 2026

Price Over Earnings Overview: Regeneron Pharmaceuticals - Benzinga

Mar 10, 2026
pulisher
Mar 10, 2026

REGN: Dupixent and EYLEA HD fuel growth as pivotal pipeline readouts approach in 2024–2025 - TradingView

Mar 10, 2026
pulisher
Mar 10, 2026

Capital International Ltd. CA Sells 5,999 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Capital International Sarl Has $26.31 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Swiss National Bank Has $172.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Russell Investments Group Ltd. Has $128.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Korea Investment CORP Purchases 5,181 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026 - Meyka

Mar 10, 2026
pulisher
Mar 09, 2026

Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial - TechTarget

Mar 09, 2026
pulisher
Mar 09, 2026

Regeneron (REGN) Reports Positive Phase 3 Results for Obesity Dr - GuruFocus

Mar 09, 2026
pulisher
Mar 09, 2026

Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights

Mar 09, 2026
pulisher
Mar 09, 2026

Regeneron stock maintained at Buy by Truist on obesity drug data - Investing.com Canada

Mar 09, 2026
pulisher
Mar 09, 2026

Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China - BioSpace

Mar 09, 2026
pulisher
Mar 09, 2026

Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Regeneron-licensed obesity drug shows positive phase 3 results in China (REGN:NASDAQ) - Seeking Alpha

Mar 09, 2026
pulisher
Mar 09, 2026

Vinva Investment Management Ltd Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Mar 09, 2026

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$700.45
price down icon 1.19%
$313.41
price down icon 1.20%
$469.34
price down icon 1.84%
biotechnology ONC
$284.05
price down icon 0.44%
$139.50
price down icon 0.01%
Capitalizzazione:     |  Volume (24 ore):